Aquaporin Initiates a Significant Rights Issue
Aquaporin A/S, a pioneering company in water technology, has announced its decision to undertake a rights issue designed to raise additional capital. This strategic move is aimed at enhancing the financial stability of the company as it navigates the complexities of the water filtration market.
Overview of the Rights Issue
The Board of Directors has resolved to launch a rights issue providing existing shareholders with pre-emptive subscription rights to purchase up to 77,536,770 new shares. Each of these new shares has a nominal value of DKK 1 and will be available at a subscription price of DKK 1 per share. If fully subscribed, the rights issue could generate gross proceeds of approximately DKK 78 million.
Comments from Leadership
According to Ulrik Lund Jakobsen, Chief Executive Officer of Aquaporin, “This rights issue is essential for maintaining our trajectory towards profitability. We have received robust validation from customers and are well-prepared to execute our strategy using the funds obtained from this offering.” He emphasizes the need for a solid financial foundation over the coming year to support operational goals.
Strategic Objectives for Capital Use
The funds raised from this offering will be directed towards reinforcing Aquaporin's operational capabilities and bolstering its research and development activities. Specifically, this includes advancements in their proprietary Aquaporin Inside® technology, which is fundamental to their membrane purification systems. The technology is anticipated to play a crucial role in future growth and product offerings, particularly in Industrial Reverse Osmosis and Forward Osmosis sectors.
Key Terms of the Offering
The rights issue is structured to provide existing shareholders with ten Pre-emptive Rights for each existing share they hold. Three Pre-emptive Rights will be necessary to subscribe for one new share. It is acknowledged that shareholders who choose not to participate in the rights issue may face significant dilution of their shares, potentially up to 77%.
Subscription Details
The subscription period for the new shares will begin on January 7, 2026, and will close on January 20, 2026. Shareholders will have the opportunity to trade their pre-emptive rights on Nasdaq Copenhagen during the designated trading period. It is crucial for shareholders to exercise their rights during this timeframe to avoid any unintended dilution.
Projected Timeline
Aquaporin has laid out a precise timeline for the rights issue, with important dates including the start of the subscription period and the expected results publication. The shares are anticipated to be admitted to trading on Nasdaq Copenhagen shortly after the closure of the subscription period, setting a foundation for increased liquidity and market engagement.
Commitments and Support from Shareholders
Aquaporin has secured advance commitments from several existing shareholders to ensure the rights issue's success. Notably, two major shareholders have pledged to participate significantly, which reflects confidence in the company's future direction. This funding will help ensure that the company can execute its strategic plans without delay or financial obstacles.
Future Prospects and Market Positioning
With a strong operational foundation and a clear growth strategy, Aquaporin is poised to continue its commitment to innovating water filtration technologies. The rights issue not only reinforces the company's financial standing but also supports its mission of addressing global water challenges. As the company progresses, its unique position in the market could see it capitalizing on increased demand for sustainable water purification solutions.
Frequently Asked Questions
What is the purpose of the rights issue by Aquaporin?
The rights issue aims to raise capital to strengthen the company's financial position and support its growth strategy in innovative water technologies.
How many new shares will be available during the rights issue?
Aquaporin will offer up to 77,536,770 new shares at a nominal value of DKK 1 each.
What are the subscription details for the new shares?
The subscription period is from January 7, 2026, to January 20, 2026, and each share will be priced at DKK 1.
Who can participate in the rights issue?
Existing shareholders registered by January 6, 2026, will receive pre-emptive rights to subscribe for the new shares.
How will the funds from the rights issue be utilized?
The proceeds will primarily fund ongoing operations, R&D initiatives, and the commercialization of the second generation of Aquaporin Inside® technology.
